Enovis

ENOV · NYSE

$20.69+$0.82 (+4.13%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $19.87

Latest news

Press releaseOct 8, 8:00 AM ETGlobe Newswire
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
NewsOct 6, 8:35 AM ET
Transcript: Enovis Q2 2026 Earnings Conference Call
Press releaseSep 22, 12:02 PM ETPRNewswire
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Press releaseSep 1, 6:45 AM ETPRNewswire
eCential Robotics Announces Binding Offer from Enovis
NewsSep 1, 6:37 AM ET
Enovis Enters Into Binding Offer To Acquire eCential Robotics For Upfront Enterprise Value Of €155 Mln
Press releaseSep 1, 6:30 AM ETGlobe Newswire
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
NewsAug 6, 6:24 AM ET
Enovis Q2 Adj. EPS $0.90 Beats $0.85 Estimate, Sales $582.782M Beat $582.542M Estimate
Press releaseAug 6, 6:05 AM ETGlobe Newswire
Enovis Announces Second Quarter 2026 Results
Press releaseJul 17, 8:00 AM ETGlobe Newswire
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
Press releaseJun 8, 8:30 AM ETGlobe Newswire
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
NewsMay 7, 6:07 AM ET
Enovis Q1 Adj. EPS $0.89 Beats $0.82 Estimate, Sales $589.200M Beat $571.131M Estimate
Press releaseMay 7, 6:01 AM ETGlobe Newswire
Enovis Announces First Quarter 2026 Results
NewsMay 4, 8:02 AM ETAvi Kapoor
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Press releaseMay 1, 1:15 PM ETBusiness Wire
Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis
NewsApr 17, 1:45 PM ETVandana Singh
Analyst Backs Enovis On Cash Flow Turnaround
Press releaseApr 10, 8:00 AM ETGlobe Newswire
Enovis to Host First Quarter 2026 Results Conference Call on May 7th
Press releaseFeb 26, 6:33 AM ETGlobe Newswire
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Press releaseFeb 26, 6:10 AM ETGlobe Newswire
Enovis Announces Fourth Quarter and Full Year 2025 Results
NewsJan 6, 7:50 AM ETAvi Kapoor
This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
NewsJan 6, 7:01 AM ET
4 Analysts Assess Enovis: What You Need To Know
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseNov 6, 6:01 AM ETGlobe Newswire
Enovis Announces Third Quarter 2025 Results
Press releaseAug 7, 6:00 AM ETGlobe Newswire
Enovis Announces Second Quarter 2025 Results
NewsJul 8, 9:00 AM ET
Assessing Enovis: Insights From 4 Financial Analysts
NewsMay 9, 5:00 PM ET
Where Enovis Stands With Analysts
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
Press releaseJan 7, 6:19 PM ETPRNewswire
Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

Transcript: Enovis Q2 2026 Earnings Conference Call

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

eCential Robotics Announces Binding Offer from Enovis

Enovis Enters Into Binding Offer To Acquire eCential Robotics For Upfront Enterprise Value Of €155 Mln

Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics

Enovis Q2 Adj. EPS $0.90 Beats $0.85 Estimate, Sales $582.782M Beat $582.542M Estimate

Enovis Announces Second Quarter 2026 Results

Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

Enovis Q1 Adj. EPS $0.89 Beats $0.82 Estimate, Sales $589.200M Beat $571.131M Estimate

Enovis Announces First Quarter 2026 Results

Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis

Analyst Backs Enovis On Cash Flow Turnaround

Enovis to Host First Quarter 2026 Results Conference Call on May 7th

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Announces Fourth Quarter and Full Year 2025 Results

This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

4 Analysts Assess Enovis: What You Need To Know

Earnings Scheduled For November 6, 2025

Enovis Announces Third Quarter 2025 Results

Enovis Announces Second Quarter 2025 Results

Assessing Enovis: Insights From 4 Financial Analysts

Where Enovis Stands With Analysts

Earnings Scheduled For May 8, 2025

Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600